Navigation Links
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Date:12/4/2013

n the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... and NEW YORK , Sept. ... SAS and the Hereditary Neuropathy Foundation (HNF) announced today ... awareness around Charcot-Marie-Tooth (CMT) disease and support the development ... Pharnext will provide financial support to several ... development of a specific section in the HNF website ...
(Date:9/15/2014)... 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... with a focus on Omega-3 therapies for cardiovascular ... Board of Directors approved the granting of stock ... close of business on Friday, September 12, 2014. ... shares of the Company were granted in accordance ...
(Date:9/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Valeant Pharmaceuticals International, will redeem all of the outstanding ... Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 (the " ... an irrevocable notice of redemption for the Notes. ... irrevocable notice of redemption with respect to the remaining ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2
... , , JERUSALEM, Israel, January 11 ... systems, today announced that it has filed two registration,statements on ... One registration statement relates to a proposed ... and warrants to purchase 12,million shares of common stock, as ...
... , SAN JOSE, Calif., Jan. 11 Finesse Solutions, ... life sciences process applications, announced the production release of ... oxygen or pH and process temperature, and TruTorr headspace ... accuracy, lifetime, and ease of use. It is available ...
Cached Medicine Technology:Oramed Pharmaceuticals Announces Filing of Two Registration Statements 2Oramed Pharmaceuticals Announces Filing of Two Registration Statements 3Single-Use Sensor Product Family Enters High Volume Production 2
(Date:9/16/2014)... Hospital announced today it is teaming up with the ... the Presenting Sponsor of the 2014-15 and 2015-16 seasons, ... partner. As the Presenting Sponsor for the next two ... inclusion on all Lightning advertising campaigns and materials throughout ... sponsorship partner of the Lightning since 2011, and it ...
(Date:9/16/2014)... of dairy food may reduce the risk of heart ... have not traditionally formed part of the diet. ... Emeritus Professor Mark Wahlqvist from Monash University,s Department of ... considered the role increased consumption of dairy foods had ... , "In a dominantly Chinese food culture, unaccustomed ...
(Date:9/16/2014)... who have had children (parous women) appear to ... breast cancer, the subtype that carries a higher ... of African ancestry. A similar relationship was ... between childbearing and increased risk of estrogen receptor-negative ... the women who had never breastfed. These findings, ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2
... HealthDay Reporter , MONDAY, Feb. 7 (HealthDay News) -- ... may be less likely to develop a tough-to-treat brain ... It,s not clear how this knowledge might improve prevention ... said the findings pave the way for further research. ...
... Feb. 7 (HealthDay News) -- The number of Americans ... economy, statistics released Monday suggest. Last year, there ... country, up five percent from 2009, the American Society ... cosmetic surgical procedures and 11.6 cosmetic minimally-invasive procedures. The ...
... State for Research and Emilio Botn, president of ... Finantial City (located in Boadilla del Monte) the ... included in PESA (Progression of Early Subclinical Atherosclerosis) ... Center for Cardiovascular Research (CNIC) and Grupo Santander ...
... radiation from cardiac imaging and other procedures after a ... cancer, found a new study published in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of procedures ... angiography and nuclear scans, is increasing which has led ...
... Geneva, Switzerland. Following the publication of several media reports ... grants financed by the Global Fund to Fight AIDS, ... all donors and governments to continue their funding. ... instrument which attracts, manages and disburses resources to prevent ...
... diseases. Gene therapy direct replacement of mutant genes by ... defects. Now a research team based at the Medical Center ... Carsten Rudolph, has taken a new approach that avoids DNA ... modification of mRNAs (the metabolically active molecules derived from genomic ...
Cached Medicine News:Health News:Allergies Linked to Lower Brain Cancer Rate in Study 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 3Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Media reports ignore that Global Fund resources deliver tremendous results in the fight against AIDS 2Health News:Save messengers -- modified mRNAs open up new therapeutic possibilities 2
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... ejection with long, lever tip ejector, Color ... tips or for greater performance use Hamilton ...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
... a system that measures the sedimentation ... rate may be relevant as input ... rate is measured in a batch ... in high-volume settings such as hospitals ...
Medicine Products: